 Daix France, Long Island City New York, United States, June 16, 2022 Inventiva Euronext Paris and Nasdaq: IVA, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis NASH and other diseases with significant unmet medical needs, announced today that it will host a webcast event focused on NASH with the participation of three Key Opinion Leaders KOLs on June 28, 2022, following the EASL International Liver CongressTM 2022. 